Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.

Latest Articles

Corporate Profile
“India has undergone a remarkable transformation”
A conversation with interim country manager Sandip Agrawal about a young and growing country

Corporate Profile
From social worker to the pharmaceutical industry
Miyuki Ono shares about an empathy program designed to provide patients with holistic support

Corporate Profile
Solidarity with Ukraine
We condemn military aggression against Ukraine and will contribute EUR 38 million to humanitarian relief funds for Ukraine.
Links

Discover our global career opportunities
We offer a wide range of career development opportunities in over 140 affiliates worldwide. Click "Read more" to check out the local career sites.

Working at Boehringer Ingelheim
As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in the world.

About us
Financial Highlights
Net sales, Research and Development expenditures, Operating Income and Personnel Capacity: Boehringer Ingelheim grows

Annual Report 2022: Generations
Our aim is to transform lives, today and for generations to come. In this annual report, our employees share amazing success stories about how, through their work, they contribute to a better and healthier world of humans and animals.
Downloads

Boehringer Ingelheim Corporate Factsheet
Find all important information about our company at a glance.

Company Profile Boehringer Ingelheim
Value through Innovation

Major consolidated companies
Overview of selected consolidated companies
Related Press Releases

August 01, 2023
First half of 2023: strong growth and expansion in key therapy areas

May 02, 2023